1-20 of 13442
Sort by
Image
Published: 26 April 2025
Fig. 1 Study design.
Image
Published: 26 April 2025
Fig. 2 Alluvial plot describing the daily activity of acid exposure time (AET), stratified by gastroesophageal reflux disease (GERD) diagnosis based on findings by the prolonged wireless capsule pH monitoring. The alluvial plot corresponds to the illustration of a longitudinal non-parametric analysis of th
Journal Article
Harumi Hashimoto and others
Diseases of the Esophagus, Volume 38, Issue 2, April 2025, doaf030, https://doi.org/10.1093/dote/doaf030
Published: 26 April 2025
Journal Article
Yusuke Fujiyoshi and others
Diseases of the Esophagus, Volume 38, Issue 2, April 2025, doaf023, https://doi.org/10.1093/dote/doaf023
Published: 21 April 2025
Image
Published: 06 April 2025
Fig. 2 Physician-reported comorbidity burden among patients with EoE aged ≥12 years by patient age. EoE, eosinophilic esophagitis; OAS, oral allergy syndrome; PFS, pollen food allergy syndrome.
Image
Published: 06 April 2025
Fig. 3 EoE symptom burden other than dysphagia as reported by physicians and patients. a,b,c,d Missing responses from patients are excluded. b For 14 patients, the caregiver reported on their behalf. c Patients were asked to report the symptoms experienced in the 7 days prior, and physicians were asked
Journal Article
N J Shaheen and others
Diseases of the Esophagus, Volume 38, Issue 2, April 2025, doaf026, https://doi.org/10.1093/dote/doaf026
Published: 06 April 2025
Image
Published: 06 April 2025
Fig. 1 EE, erosive esophagitis; ICD-10 Dx, International Classification of Diseases, Tenth Revision diagnosis.
Image
Published: 06 April 2025
Fig. 3 EE, erosive esophagitis.
Image
Published: 06 April 2025
Fig. 4 EE, erosive esophagitis; PPI, proton pump inhibitor; LOT, line of therapy. Note: Total costs calculation includes those with no record of a pharmacy fill for PPI.
Image
Published: 06 April 2025
Fig. 4 EoE-IQ impact of EoE symptoms in previous 7 days. a,b Missing responses excluded. b Score range 1–5, where the score of 1 indicates ‘no impact,’ and 5 indicates ‘extremely high impact.’ EoE, eosinophilic esophagitis; EoE-IQ, EoE Impact Questionnaire.
Journal Article
Alain M Schoepfer and others
Diseases of the Esophagus, Volume 38, Issue 2, April 2025, doaf024, https://doi.org/10.1093/dote/doaf024
Published: 06 April 2025
Image
Published: 06 April 2025
Fig. 1 Pharmaceutical treatments currently received by patients with EoE aged ≥12 years for treatment of EoE as reported by physicians. Note: Corticosteroids include budesonide, ciclesonide, betamethasone, prednisone, other (unspecified); PPIs include omeprazole, lansoprazole, dexlansoprazole, esomeprazole
Image
Published: 06 April 2025
Fig. 2 Blue—dexlansoprazole, lansoprazole, esomeprazole, or rabeprazole; yellow—multiple PPI; green—no subsequent LOT; red—omeprazole; purple—pantoprazole; EE, erosive esophagitis; LOT, line of therapy.
Image
Published: 03 April 2025
Fig. 1 Clinical yield of esophagogastroduodenoscopy (EGD) and 24 h pH-impedance (pH-MII) testing in children that were referred for (A) dysphagia; (B) gastroesophageal reflux (GER) symptoms: regurgitation and/or heartburn; or (C) a combination of GER and dysphagia symptoms. For each performed test, we asse
Journal Article
M van Lennep and others
Diseases of the Esophagus, Volume 38, Issue 2, April 2025, doaf022, https://doi.org/10.1093/dote/doaf022
Published: 03 April 2025
Image
Published: 02 April 2025
Figure 2 Pre and post treatment GERD-HRQL scores
Image
Published: 02 April 2025
Figure 1 Proposed hypothesis for the relationship between GERD, GERD-like symptoms and intestinal dysbiosis
Image
Published: 02 April 2025
Figure 3 Pre and post treatment LPRHRQL scores
Journal Article
Swathikan Chidambaram and others
Diseases of the Esophagus, Volume 38, Issue 2, April 2025, doaf001, https://doi.org/10.1093/dote/doaf001
Published: 02 April 2025